<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056389</url>
  </required_header>
  <id_info>
    <org_study_id>202644</org_study_id>
    <nct_id>NCT05056389</nct_id>
  </id_info>
  <brief_title>Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)</brief_title>
  <official_title>Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer - Feasibility Study (NIPEC-OXA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility study regarding 20 Patients with peritoneal metastases from colorectal cancer&#xD;
      treated with cytoreductive surgery and HIPEC and subsequently with 4 courses of normothermic&#xD;
      intraperitoneal chemotherapy - long term (NIPEC-OXA) with oxaliplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: to determine if the administration of additional i.p. chemotherapy for a&#xD;
      period of 9 weeks after completed CRS and HIPEC is a safe procedure to be used in the future&#xD;
      in a formal randomised trial. The toxicity of the chemotherapy given through i.p. during&#xD;
      NIPEC-OXA courses will be analysed throughout the entire treatment period and a subsequent&#xD;
      3-month follow-up period.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        1. Intra-abdominal chemotherapy drug distribution 7-14 days after CRS and HIPEC and before&#xD;
           the 4th NIPEC-OXA course&#xD;
&#xD;
        2. Surgical complications after CRS, HIPEC and NIPEC-OXA until 3 months after the last&#xD;
           NIPEC-OXA course&#xD;
&#xD;
        3. Disease-free survival (DFS)&#xD;
&#xD;
        4. Overall survival (OS)&#xD;
&#xD;
      Exploratory endpoint: quality of life&#xD;
&#xD;
      Estimated date of first patient enrolled: 3rd quarter of 2021 Anticipated recruitment period:&#xD;
      1,5 years Estimated treatment completion date of last patient: 1st quarter of 2023 Expected&#xD;
      treatment duration per patient: 9 weeks Expected follow-up period per patient: 3 months after&#xD;
      the last NIPEC-OXA procedure&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Feasibility study with 20 eligible patients with peritoneal metastases from colorectal cancer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events after Intraperitoneal Chemotherapy Administration (NIPEC-OXA)</measure>
    <time_frame>Throughout the entire treatment period, including a 3-month follow-up</time_frame>
    <description>Common Terminology Criteria for Adverse Events v. 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Surgical Complications after CRS, HIPEC and NIPEC-OXA</measure>
    <time_frame>Throughout the entire treatment period, including a 3-month follow-up</time_frame>
    <description>Clavien-Dindo classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Optimal, Suboptimal and Missing Fluid Distribution in the Abdomen Injected Through 2 I.P. Catheters</measure>
    <time_frame>7-14 days after CRS and HIPEC and before the 4th NIPEC-OXA course</time_frame>
    <description>CT scans with intraperitoneal contrast</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peritoneal Metastases</condition>
  <condition>Colo-rectal Cancer</condition>
  <arm_group>
    <arm_group_label>NIPEX-OXA arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients treated with NIPEC-OXA after CRS and HIPEC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administration of oxaliplatin intraperitoneally</description>
    <arm_group_label>NIPEX-OXA arm</arm_group_label>
    <other_name>Intraperitoneal catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 75 years&#xD;
&#xD;
          -  Able to provide written, informed consent regarding expected cooperation during&#xD;
             treatment and follow-up according to ICH GCP, and national/local regulations&#xD;
&#xD;
          -  Histologically verified CRC&#xD;
&#xD;
          -  Histologically verified and/or radiologically/clinically suspected PM from CRC&#xD;
&#xD;
          -  Synchronous or metachronous PM from CRS&#xD;
&#xD;
               -  If neoadjuvant oxaliplatin-containing chemotherapy is administrated, patients&#xD;
                  with absence of progressive disease (assessed by CT)&#xD;
&#xD;
               -  In metachronous cases: if adjuvant oxaliplatin-containing chemotherapy, the&#xD;
                  interval between oxaliplatin- containing adjuvant chemotherapy and diagnosis of&#xD;
                  PM must be &gt;6 months&#xD;
&#xD;
          -  Intraperitoneal tumour burden amenable to CRC and HIPEC with Peritoneal Cancer Index&#xD;
             (PCI40) â‰¤ 20, assessed at the time of surgery&#xD;
&#xD;
          -  Absence of other metastatic sites, i.e. liver, lungs, central lymph nodes&#xD;
&#xD;
          -  Completeness of Cytoreduction (CC) score of 0 is required&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status either 0 or 141&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP), defined as all women physiologically capable&#xD;
             of becoming pregnant, should have a negative urine- or serum pregnancy test within 72&#xD;
             hours prior to receiving the 1st dose of study medication. If the urine test is&#xD;
             positive or cannot be confirmed as negative, a serum pregnancy test will be required.&#xD;
&#xD;
          -  WOCBP should be willing to use 1 highly effective method of birth control or be&#xD;
             surgically sterile, or abstain from heterosexual activity for the course of the study&#xD;
             through 120 days after the last dose of study medication.&#xD;
&#xD;
          -  Men in a sexual relationship with a WOCBP must agree to use a condom starting with the&#xD;
             1st dose of study therapy through 120 days after the last dose of study therapy. In&#xD;
             case of female partner of child-bearing potential, the female partner should use 1&#xD;
             highly effective contraception method as defined in section 5.1.5 - &quot;Other&#xD;
             considerations&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of hypersensitivity to oxaliplatin or to any of the excipients listed in&#xD;
             the SmPC section 6.1&#xD;
&#xD;
          -  Has myelosuppression before starting treatment, ie number of neutrophils granulocytes&#xD;
             &lt;1.0 x 109/l and/or number of platelets &lt;75 x 109/l&#xD;
&#xD;
          -  Has peripheral sensitive neuropathy with functional outcomes before starting treatment&#xD;
&#xD;
          -  Has severe renal impairment (creatinine clearance &lt; 30 ml min) (see the SmPC section&#xD;
             5.2).&#xD;
&#xD;
          -  Concurrent or previous diagnosis of invasive cancer within 5 years&#xD;
&#xD;
          -  Psychiatric or addictive disorder or other medical condition that would preclude the&#xD;
             patient from meeting the trial requirements&#xD;
&#xD;
          -  Participation in another cancer clinical trial&#xD;
&#xD;
          -  Patients who, according to current guidelines will be offered i.v. adjuvant therapy&#xD;
&#xD;
          -  Significant cardiac or other medical illness that would limit activity or survival,&#xD;
             such as severe congestive heart failure, unstable angina, or serious cardiac&#xD;
             arrhythmia&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not participate&#xD;
&#xD;
          -  Has a known history of Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected)&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             project duration of the trial, starting with the screening visit through 120 days&#xD;
             after the last dose of trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariusz Goscinski, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, The Norwegian Radium Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariusz Goscinski, MD.PhD.</last_name>
    <phone>004793497857</phone>
    <email>mariuszg@online.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vegar Dagenborg, MD,PhD.</last_name>
    <email>vegdag@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Norwegian, Radium Hospital, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariusz Goscinski, MD, PhD</last_name>
      <phone>004793497857</phone>
      <email>mariuszg@online.no</email>
    </contact>
    <contact_backup>
      <last_name>Vegar Dagenborg, MD, PhD</last_name>
      <email>vegdag@ous-hf.no</email>
    </contact_backup>
    <investigator>
      <last_name>Mariusz Goscinski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vegar Dagenborg, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Svein Dueland, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stein Larsen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kjersti Flatmark, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Li, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Mariusz Goscinski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>NIPEC-LT</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>CRS</keyword>
  <keyword>HIPEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The sponsor's representatives (e.g. monitors, auditors) and/or regulatory authorities will be allowed access to source data for source data verification in which case a review of those parts of the hospital records relevant to the study may be required.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data of the study will be kept 15 years after the end of the study according Norwegian law.</ipd_time_frame>
    <ipd_access_criteria>Access to the data has to be approved by the PI.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

